{"id":2083,"date":"2018-06-26T08:00:47","date_gmt":"2018-06-26T06:00:47","guid":{"rendered":"https:\/\/xd3kj9bvqee.preview.infomaniak.website\/?p=2083"},"modified":"2018-06-21T16:41:24","modified_gmt":"2018-06-21T14:41:24","slug":"novacap-strengthens-its-us-pharmaceutical-offer-with-acquisition-of-pci-synthesis","status":"publish","type":"post","link":"https:\/\/www.industries-cosmetiques.fr\/en\/novacap-strengthens-its-us-pharmaceutical-offer-with-acquisition-of-pci-synthesis\/","title":{"rendered":"Novacap strengthens its US pharmaceutical offering with the acquisition of PCI Synthesis"},"content":{"rendered":"
\n
\n
\n
\n
\n
\n
\n
\n

Novacap, a global player in pharmaceutical synthesis and specialty products, announces the signature of an agreement to acquire PCI Synthesis, a US company specializing in the development and contract manufacturing of pharmaceutical ingredients (CDMO ).
\nLocated in the heart of the Boston area's pharmaceutical and biotechnology hub, PCI Synthesis offers its customers a wide range of services including research and process development, clinical development and commercial production of active pharmaceutical ingredients and other specialty intermediates.
\nThe company operates an R&D center in Devens (Massachusetts) and a manufacturing site in Newburyport (Massachusetts), and generates sales of $32 million. PCI has grown significantly in recent years, positioning itself as a strategic partner to the U.S. pharmaceutical and biotech industries, thanks to a wide range of services and technologies, strong responsiveness and recognized project management skills.
\nThe combination of the two companies will give PCI Synthesis the resources it needs to pursue its development, and will strengthen Novacap's pharmaceutical synthesis capabilities, which now include 12 cGMP sites, 2 main R&D centers and a comprehensive range of services and technologies to support customers throughout the clinical and commercial phases.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
\"Novacap's acquisition validates our strategy and business model, and rewards the commitment of our employees. Since the company was founded over 20 years ago, we have never ceased to evolve and innovate, and we will continue to do so thanks to the merger with Novacap. We will now have access to Novacap's technical expertise so that we can serve our customers even better\", says Ed Price, founder and president of PCI Synthesis.<\/div>\n<\/div>\n<\/div>\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n
\n
\n
\n

\u00a0\"The acquisition of PCI Synthesis is perfectly in line with the Group's strategy of strengthening our offering to the pharmaceutical industry and accelerating our development in the United States. We have been impressed by PCI's success, its pipeline of projects and its growth prospects. Our two companies have complementary CDMO activities and share common values such as entrepreneurship, operational excellence and customer focus. We look forward to working with the PCI teams\", said Pierre Luzeau, CEO of PCI. said Pierre Luzeau, President of Novacap Group.<\/p>

Advertising<\/div>
\"site-industries-cosmetiques<\/a><\/div><\/div>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n
\n

Completion of this acquisition remains subject to approval by the competition authorities.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

Novacap, acteur mondial de la synth\u00e8se pharmaceutique et des produits de sp\u00e9cialit\u00e9s, annonce la signature d\u2019un accord en vue d\u2019acqu\u00e9rir PCI Synthesis, soci\u00e9t\u00e9 am\u00e9ricaine sp\u00e9cialis\u00e9e dans le d\u00e9veloppement et la fabrication \u00e0 fa\u00e7on d\u2018ingr\u00e9dients pharmaceutiques (CDMO ). Situ\u00e9e au c\u0153ur du hub pharmaceutique et biotechnologique de la r\u00e9gion de Boston, PCI Synthesis offre \u00e0 ses […]<\/p>\n","protected":false},"author":3,"featured_media":2084,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"external_url":"","footnotes":""},"categories":[51],"tags":[61],"class_list":{"0":"post-2083","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-ingredients","8":"tag-info-marche"},"acf":{"nc":null,"nc2":null,"nc3":null,"nc4":null,"nc5":null},"_links":{"self":[{"href":"https:\/\/www.industries-cosmetiques.fr\/en\/wp-json\/wp\/v2\/posts\/2083","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.industries-cosmetiques.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.industries-cosmetiques.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.industries-cosmetiques.fr\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.industries-cosmetiques.fr\/en\/wp-json\/wp\/v2\/comments?post=2083"}],"version-history":[{"count":0,"href":"https:\/\/www.industries-cosmetiques.fr\/en\/wp-json\/wp\/v2\/posts\/2083\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.industries-cosmetiques.fr\/en\/wp-json\/wp\/v2\/media\/2084"}],"wp:attachment":[{"href":"https:\/\/www.industries-cosmetiques.fr\/en\/wp-json\/wp\/v2\/media?parent=2083"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.industries-cosmetiques.fr\/en\/wp-json\/wp\/v2\/categories?post=2083"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.industries-cosmetiques.fr\/en\/wp-json\/wp\/v2\/tags?post=2083"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}